ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Successful palliative hypofractionated radiotherapy with superficial hyperthermia for heavily pretreated cutaneous breast cancer lesions.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypofractionated radiotherapy has been successfully shown to reduce pain and skin lesion bleeding. In previously irradiated areas, the effect of hypofractionated radiotherapy (weekly 4 Gy radiotherapy to a total dose of 20 Gy) can be enhanced by hyperthermia: increasing temperatures in target areas up to 43 °C. Superficial hyperthermia in combination with radiotherapy is a proven and widely applied treatment for recurrent breast cancer and malignant melanoma. Literature on the use of radiotherapy to cause hemostasis of the skin is available; however, the role of hyperthermia in combination with radiotherapy for this indication is not yet described. SHORT COMMUNICATION: We present a 72-year old woman with a history of breast cancer with painful and bleeding cutaneous metastases in the right upper arm and right breast which had a large impact on her quality of life. The metastases progressed under T‑deruxtecan treatment, and she was referred for re-irradiation to control the bleeding skin. Hyperthermia was added as a tumor-selective radiosensitizer to the radiotherapy fractions to enhance irradiation. The main treatment goal was to reduce bleeding and itching of the cutaneous lesions. The patient was treated once a week with hyperthermia immediately followed by 4 Gy radiotherapy fractions for 5 consecutive weeks. Bleeding was already decreased during the treatment series and the skin healed within 4 weeks after therapy.
conclusionTreatment with 5 × 4 Gy radiotherapy combined with hyperthermia sessions was a successful palliative therapy for bleeding cutaneous metastases. The treatment schedule was well-tolerated and the skin fully recovered within 1 month.
Indexed as
Identifiers
42329260What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.